COMPUTED DESCRIPTORS
| Molecular Weight | 351.76 g/mol |
|---|---|
| XLogP3 | -2.9 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 5 |
| Exact Mass | 351.0291840 g/mol |
| Monoisotopic Mass | 351.0291840 g/mol |
| Topological Polar Surface Area | 167 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 522 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Upacicalcet is an agonist of calcium-sensing receptors (CaSR), with potential use in the treatment of secondary hyperparathyroidism (SHPT). Upon administration, upacicalcet targets and binds to CaSRs expressed on the membranes of cells in the parathyroid glands, which suppresses osteoclast activity and reduces the excessive secretion of parathyroid hormone (PTH). This prevents the excessive PTH-mediated efflux of phosphorus and calcium from bone into the blood and normalizes serum calcium and phosphorus levels. Upacicalcet may decrease the risk of bone fracture, may lower depositions of phosphorus and calcium salts in non-bone tissues, may reduce bone and joint pain and may slow the progression of other diseases related to increased levels of PTH. CaSR controls calcium homeostasis and regulates the release of PTH.